What changed: Chronic lymphocytic leukaemia, first treatment

When this page itself was last checked or edited.

Fixed-duration acalabrutinib + venetoclax, previously untreated CLL/SLL without del(17p)/TP53 (AMPLIFY)

A milestone in how this cancer is treated.

3-year PFS 76.

Ibrutinib delayed progression to symptomatic disease but did not improve survival: five-year overall survival 93.

5-year PFS 81.

A milestone in how this cancer is treated.

PFS HR 0.

A milestone in how this cancer is treated.

CR 55%; uMRD 77%; 4-year PFS ~79%.

PFS HR 0.

Previously untreated CLL with venetoclax, fixed duration (CLL14); with acalabrutinib (ELEVATE-TN)

6-year PFS 53.

6-year median PFS not reached vs 27.

A milestone in how this cancer is treated.

Ibrutinib improved progression-free and overall survival over chlorambucil in older patients with untreated CLL; approved for first-line CLL in March 2016.

A milestone in how this cancer is treated.

Previously untreated CLL with chlorambucil (CLL11)

A milestone in how this cancer is treated.

A milestone in how this cancer is treated.